Large-cap laggards slid on weak results/guidance, cuts and capital moves—led by The Trade Desk, Fortinet, Super Micro, ...

A legacy ranch in Jackson Hole, WY, has come onto the market, with records showing it is owned by former Eli Lilly exec Dr.

Eli Lilly is seeing strong growth from its weight loss drugs. Investors are nervous about tariffs on drugs and weak data from ...

Orforglipron, the new weight loss pill manufactured by Eli Lilly, helped patients in a recent study lose a significant amount ...

Eli Lilly is one step closer to bringing an oral weight loss medicine to the booming obesity drug market. A clinical trial ...

In the wake of this sell-off, a critical question arises about whether LLY stock represents a buying opportunity.

In May, it announced it would acquire SiteOne Therapeutics, a drugmaker with a promising investigational medicine for pain.

The stock is struggling badly, and if things don't improve in short order, Eli Lilly will be on track for its worst ...

The S&P 500 may have stalled on Thursday, but the Nasdaq hit a new high, as a week of positive earnings surprises and rising ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

The Dow and S&P 500 eased on Thursday, as shares of Eli Lilly dropped after data from its oral weight loss drug disappointed, ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...